CN Patent

CN116098916B — 马立巴韦在制备抗h13亚型aiv药物中的应用

Assigned to Institute Animal Science and Veterinary Medicine of Shandong AAS · Expires 2024-03-22 · 2y expired

What this patent protects

本发明属于医药技术领域，具体涉及马立巴韦在抗H13亚型AIV药物中的应用。本发明首次发现化合物马立巴韦能够有效抑制H13亚型AIV的增殖，且对细胞的毒性小，经实验证明，马立巴韦对MDCK细胞的半数细胞毒性浓度(CC50)是大于等于100μM，而对H13亚型AIV病毒的半数有效浓度(EC50)为19.03μM；马立巴韦对H13亚型AIV的治疗指数大于等于5.25，表明其具有开发成抗H13亚型AIV药物的前景，为马立巴韦开辟了新的药物用途，也为开发高效特异的抗H13亚型AIV药物奠定实验基础并提供新的视野。

USPTO Abstract

本发明属于医药技术领域，具体涉及马立巴韦在抗H13亚型AIV药物中的应用。本发明首次发现化合物马立巴韦能够有效抑制H13亚型AIV的增殖，且对细胞的毒性小，经实验证明，马立巴韦对MDCK细胞的半数细胞毒性浓度(CC50)是大于等于100μM，而对H13亚型AIV病毒的半数有效浓度(EC50)为19.03μM；马立巴韦对H13亚型AIV的治疗指数大于等于5.25，表明其具有开发成抗H13亚型AIV药物的前景，为马立巴韦开辟了新的药物用途，也为开发高效特异的抗H13亚型AIV药物奠定实验基础并提供新的视野。

Drugs covered by this patent

Patent Metadata

Patent number
CN116098916B
Jurisdiction
CN
Classification
—
Expires
2024-03-22
Drug substance claim
No
Drug product claim
No
Assignee
Institute Animal Science and Veterinary Medicine of Shandong AAS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.